Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bevespi · 1 trial · 1 indication
Echocardiographic assessment of PVR before and after inhalation of 180 μg albuterol as a test of endothelial function
| Arm | Type | Description |
|---|---|---|
| Bretzri followed by Bevespi Group | EXPERIMENTAL | Participants in this group will receive Bretzri for 4-weeks followed by 8-weeks of Bevespi. |
| Bevespi followed by Bretzri Group | EXPERIMENTAL | Participants in this group will receive Bevespi for 8-weeks followed by 4-weeks of Bretzri. |
| Name | Type | Description |
|---|---|---|
| Bevespi | DRUG | Two puffs twice a day |
| Bretzri | DRUG | Two puffs twice a day |
Inclusion Criteria: * physician diagnosis of COPD * former smoking history of more than 10 pack-years * baseline post-bronchodilator one-second forced expiratory volume (FEV1) 50-80% of predicted, baseline FEV1 and forced vital capacity (FVC) ratio \<0.7 * males and females, 40-80 years of age * re...
Bevespi is being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is an investigational small molecule therapy in Phase 2 clinical development. The only listed trial for Bevespi is in adults aged 40 years and older with COPD, and it is not currently approved for any indication.
Bevespi is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the Phase 2 trial evaluating Bevespi in Chronic Obstructive Pulmonary Disease. No other developers or partners are listed for this asset.
Bevespi is in Phase 2 clinical development. The single listed trial, NCT05607719, is a Phase 2 study that is currently active but not recruiting. Bevespi has not completed any trials and is not approved for any indication.
Bevespi is being evaluated in one clinical trial: NCT05607719, titled "Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD." This Phase 2 trial is active but not recruiting, has an estimated enrollment of 30 participants, and is being conducted in the United States.